monitoring the safety of influenza a h1n1 2009 monovalent vaccines l.
Skip this Video
Loading SlideShow in 5 Seconds..
Monitoring the Safety of Influenza A (H1N1) 2009 Monovalent Vaccines PowerPoint Presentation
Download Presentation
Monitoring the Safety of Influenza A (H1N1) 2009 Monovalent Vaccines

Loading in 2 Seconds...

play fullscreen
1 / 56
Download Presentation

Monitoring the Safety of Influenza A (H1N1) 2009 Monovalent Vaccines - PowerPoint PPT Presentation

Download Presentation

Monitoring the Safety of Influenza A (H1N1) 2009 Monovalent Vaccines

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Monitoring the Safety of Influenza A (H1N1) 2009 Monovalent Vaccines Claudia Vellozzi, MD, MPH Immunization Safety Office Division of Healthcare Quality Promotion Centers for Disease Control and PreventionAtlanta, GA November 18, 2009

  2. Overall Objectives for 2009 H1N1 Vaccine Safety Monitoring Identify clinically significant adverse events following receipt of 2009 HINI vaccine in a timely manner Rapidly evaluate serious adverse events following receipt of 2009 H1N1 vaccine and determine public health importance Evaluate if there is a risk of Guillain-Barré syndrome (GBS) associated with the 2009 H1N1 vaccine Communicate vaccine safety information in a clear and transparent manner to healthcare providers, public health officials, and the public

  3. Today’s Objectives • Describe the CDC’s Immunization Safety Office surveillance systems for monitoring the safety of 2009 H1N1 vaccine • Provide preliminary data from each of these systems

  4. Vaccine Safety Datalink (VSD): Background • Established in 1990 • A collaborative project among CDC and 8 managed care organizations (MCOs) • Allows for planned immunization safety studies as well as timely investigations arising from • hypotheses from medical literature and pre-licensure • reports to the Vaccine Adverse Event Reporting System (VAERS) • changes in immunization schedules, or the introduction of new vaccines • Since 2005, conducts routine Rapid Cycle Analysis (RCA) of newly licensed and approved vaccines or modifications to existing vaccine recommendations

  5. VSD Population • Collects medical care and vaccination data on more than 9.5 million members annually (3.1% of the US population) • As of 12/31/2008: • 2,252,024 children (<18) enrolled • 3.0% of US population • 7,245,835 adults (≥18) enrolled • 3.1% of US population • Average yearly birth cohort ~ 95,000

  6. Group Health Cooperative Health Partners Marshfield Clinic AHIP Kaiser Permanente Colorado So. CA Kaiser Permanente CDC VSD Sites: 2009 Northwest Kaiser Permanente Harvard Pilgrim No. CA Kaiser Permanente

  7. Hospital discharge diagnosis codes Enrollment and demographics + Linked by Study IDs Outpatient and Clinic visits Birth and death certificate information VSD Data Files + Chart Review Immunizations Records

  8. VSD 2009 H1N1 Vaccine Safety Monitoring Specific Aims • Conduct rapid surveillance of 2009 H1N1 vaccine safety using • self controlled case series (SCCS) using binomial maximized sequential probability ratio tests (maxSPRT) • comparisons with historical seasonal influenza vaccines using Poisson maxSPRT • Conduct comprehensive analyses after immunization program is completed of associations between H1N1 vaccine and adverse events using a variety of statistical methods • Confirmatory Logistic Regression, SCCS, others (as needed)

  9. Vaccination • ------------------------------------------------------------------------------------------- Days -56 -15 0 42 84 • Unexposed (pre)ExposedUnexposed (post) SCCS Example

  10. VSD 2009 H1N1 Vaccine Adverse Events under surveillance • GBS – first ever and first in a year diagnosis, complemented by chart review • Demyelinating disease • Disorders of the peripheral nervous system and neuropathies • Seizures (epilepsy, convulsions) • Encephalitis, myelitis, encephalomyelitis • Bell’s Palsy • Other cranial nerve disorders (Facial nerve disorders, Trigeminal nerve disorders) • Ataxia (other cerebellar ataxia, ataxia) • Anaphylaxis • Angioneurotic edema, Allergic Reaction, Urticaria • Myocarditis and pericarditis (LAIV only) • Hemorrhagic stroke (subarachnoid hemorrhage, intracerebral hemorrhage, other and unspecified intracranial hemorrhage) • Ischemic stroke (excludes transient ischemic attack) • Wheezing (LAIV only) • Asthma, wheezing, respiratory distress/insufficiency, other diseases of trachea/bronchi • Multiple definitions with and without bronchiolitis • Pregnancy Outcomes – • Spontaneous Abortions, Stillborn & Pre-eclampsia, eclampsia • Adjuvanted Outcomes – • Autoimmune hepatitis and Thrombocytopenia

  11. VSD 2009 H1N1 Vaccine Pregnancy Studies • Active surveillance in pregnant women • Outcomes: Fever (>100° F),allergic reactions, miscarriage, stillbirth, premature labor and preeclampsia (includes 2 VSD sites) • Retrospective analysis evaluating the safety of 2009 H1N1 vaccines in pregnant women and their offspring (includes all VSD sites)

  12. VSD 2009 H1N1 Vaccine Pregnancy Studies Conduct a survey of pregnant women who receive any combination of seasonal or H1N1 vaccines or refuse vaccination (includes one VSD site) Specific Aims • Assess where and when pregnant women are vaccinated and if not vaccinated—why not • Accurately capture pregnancy related start dates for future linkage with the electronic medical record • Assess non-medically attended AEs • Systemic and local reactions (Fever, chills, headache, swelling, etc.) • ILI and URI symptoms, GI symtoms, sleep disturbances, other

  13. VSD 2009 H1N1 Vaccine Doses Administered as of Nov 13, 2009 206,150 Inactivated Doses

  14. VSD 2009-10 Seasonal Vaccine Doses Administered as of Nov 13, 2009

  15. VSD 2009-10 Seasonal Influenza Vaccine Safety Preliminary Findings

  16. 2009-10 Seasonal Trivalent Inactivated Influenza Vaccine (TIV): SCCS –preliminary results TotalDoses Administered– 2,045,127

  17. 2009-10 Seasonal TIV Historical Comparison-preliminary results Total Doses Administered: 2,045,127

  18. VSD 2009 H1N1 Safety Preliminary Findings

  19. 2009 H1N1 MIV: Historical Comparison-Preliminary Results Total Doses Administered – 206,150

  20. Summary • No potential associations or signals have been identified following the monitoring of 2009-10 Seasonal TIV (2,045,127) and LAIV (100,366) doses • 2009 H1N1 influenza vaccines have only recently begun to be administered in the VSD MCOs and data are insufficient to assess the safety of the vaccines • The VSD will continue to monitor both seasonal and H1N1 influenza vaccines on a weekly basis

  21. EIP Guillain-Barré Syndrome (GBS) Surveillance Project:Association of Influenza A (H1N1) 2009 Vaccine and GBS

  22. New York Minnesota Oregon California Colorado Maryland Tennessee New Mexico Georgia Population: ~ 44.9 million EIP GBS Surveillance Sites, 2009-2010 Connecticut

  23. EIP Guillain-Barré Surveillance (GBS) Surveillance Project • CDC's Emerging Infections Program (EIP) • partnership of state and local health departments, academic centers, and CDC • performs surveillance and public health research on emerging infections • October 1, 2009 time limited surveillance for GBS • Objectives: • Rapidly detect cases of GBS and report (with vaccination status) • Assess and measure if there is an association between 2009 (H1N1) vaccine and GBS • Methods: • Population ~45 million persons (statewide in CT, MD, MN, NM, TN and selected regions of CA, CO, GA, NY, and OR) • Active network of neurologists and acute care facilities contacted weekly • Report all GBS cases, standardized case finding, medical record abstraction, patient interviews • Calculation of measures of association

  24. reported weekly to CDC 10 EIP (40 million) Brighton 1, 2 Confirmed Clinical Network * Active Case-Finding Possible Cases Brighton 3 Probable Patient Interviews Record review; contact provider; antecedent & vaccine history Additional: Hospital discharges Passive provider reporting (reportable condition) AAN educational initiative; VAERS Info pending Indeterminate Exclusion (non-cases) [Brighton not met or other neurologic diagnosis] Re-assess at 14 days EIP Guillain-Barre Surveillance Case Finding * Weekly query with established network of neurology providers, sentinel pharmacies

  25. Descriptive Epidemiology of GBS Active Case Finding, Oct 1-Nov 9, 2009 *

  26. Descriptive Epidemiology of GBS Active Case Finding, Nov 9, 2009

  27. Select Methods Using Vaccine Coverage Data • Observed vs. historical GBS rates • Compares observed no. GBS cases occurring within 42 days of H1N1 vaccination to expected no. among vaccinees • Earliest incidence metric • Limitations: • historical rate comparison (may not be valid comparison, different case finding) • Initially only crude, or age-specific with assumptions on vaccine administration • With BFRSS data, fewer assumptions needed for age-specific comparisons • GBS rates in vaccinated vs. unvaccinated persons • Use BFRSS vaccine coverage data, calculate person-time exposed and unexposed to vaccine, calculate rates • Strength: rates in vaccinated and unvaccinated persons will both be calculated from active surveillance data • Limitations • BRFSS data not available until mid-November and may only be available at the state level (not EIP catchment area specific) • GBS rates in H1N1 vaccinated vs. seasonal vaccine recipients • Use BFRSS vaccine coverage data • Age-adjust

  28. Real Time Immunization Monitoring System (RTIMS) Contributors: • Johns Hopkins Bloomberg School of Public Health (JHU) • CDC ISO (AHIP) • WorldAPP (WA) • State and local health departments (HD) • Hospitals, schools, clinics, pharmacies

  29. RTIMS • Automated web-based surveillance system • Captures self reported data from vaccine recipients • Predecessor: Telewatch • Used for monitoring patients with chronic diseases • Modified for monitoring yellow fever vaccine1 • Piloted for influenza vaccine November 2008 • Capacity: • On line and database: 1-10 million vaccine recipients • Follow-up personnel: expandable

  30. Objectives To monitor influenza vaccine recipients for adverse events (early signal detection) To identify host factors associated with adverse events To compare rates of adverse events associated with different influenza vaccine products To expedite reporting of AEs to VAERS

  31. Study Population Seasonal & 2009 H1N1 Influenza vaccine recipients Target population – Pregnant women, health care workers, school aged children State & local health departments, hospitals, schools and OB clinics

  32. Timeline for Surveys Baseline survey 1st Follow up Pregnancy Follow-up? 2nd Follow-up Day 2 Day 7 Day 42

  33. Study Information CardProvided at Time of Vaccination Front Back

  34. RTIMS Information Flow Permission to Contact at Time of Vaccination or Electronic (Registries) or Vaccine Recipient Paper website sign-up Weblinks CDC, JHU, HDs link JHU Data entry Formatting WorldAPP RTIMS Survey 3-4 min initial <1 min follow-up

  35. State Participation - Active Capture(31 Contacted)

  36. 4,730 Baseline Surveysby Risk Group and Genderas of Nov 9, 2009

  37. Type of Vaccine Received by Risk Groupas of Nov 9, 2009

  38. Diagnoses after Flu Vaccineby Vaccineas of Nov 9, 2009

  39. Limitations • Surveys after vaccination • Possible selection bias: • Females more likely to participate • Persons with reactions more likely to complete? • Drop outs? • Some reluctance to have VAERS form filed • name and contact information • Active solicitation of symptoms • Some multiple symptoms

  40. Acknowledgements • VSD • Eric Weintraub • James Baggs • Frank DeStefano • CDC/EIP • Melissa Viray • Paige Lewis • Oliver Morgan • Scott Fridkin • RTIMS • Neal Halsey • Rosanna Setse

  41. Extra slides

  42. CDC “Direct” SAS Programs, Logs, Output, & Analytical Datasets Hub “Indirect” The VSD Distributed Data Model

  43. VSD 2009 H1N1 Vaccine Study Design and Analytic Plan • Challenges for studying the safety of influenza vaccines • Confounding by indication • Vaccine recommendations have expanded and changed • Influenza vaccines are often given over a very short period of time. • Individuals may have received vaccine outside their MCO (count as unvaccinated) • Seasonality of adverse events may confound interpretation • To address the challenges to monitor 2009 H1N1 safety more than one approach will be included in both: • Rapid Cycle Analyses (RCA) weekly surveillance (near real time and critical to rapid safety assessment) • End of season analysis

  44. VSD Methodological approaches in evaluating H1N1 vaccine safety

  45. VSD 2009 H1N1 Vaccine Adverse Event Definitions • Risk periods (windows) • AE-specific as described in published studies or biologic plausibility • Length of windows – vary from 2 to 60 days • Day of vaccination included in the risk period if it is biologically plausible for AE to occur same day of vaccination (e.g., anaphylaxis). • To improve the specificity • Limit to AEs occuring in inpatient or ED settings • First event to occur in a year • For AEs that may have more than one “new” onset in a year a shorter period of time will be included in analysis (ex;wheezing, seizures)

  46. How the VSD Evaluates Signals • Check data quality • Check inputs, background incidences, i.e. temporal trends • Check whether comparison groups are defined appropriately • Conduct the analysis using a different control group (e.g., concurrent vs. historical) or different vaccine • Conduct a temporal scan to see if outcomes cluster during a post-vaccination time window • Conduct a definitive study using logistic regression analysis • Review charts to confirm or exclude cases as true cases

  47. Weekly maxSPRT Results for GBS, Age ≥6 Months, 2007/08 Season

  48. Centers For Disease Control, VSD team James Baggs, PhD Julianne Gee, MPH Natalie McCarthy, MPH Eric Weintraub, MPH Kaiser Permanente of No. California (NCK), Oakland CA Roger Baxter, MD Nicky Klein, MD, PhD Ned Lewis Northwest Kaiser Permanente (NWK), Portland OR Allison Naleway, PhD John Mullooly, PhD Karen Riedlinger Lois Drew Harvard Pilgrim /Harv. Vanguard (HAR) Boston, MA Tracy Lieu, MD, MPH Richard Platt, MD, MSc Katherine Yih, PhD, MPH Richard Fox Grace Lee, MD, MPH Sharon Greene, MD, MPH Group Health Cooperative (GHC), Seattle WA Lisa Jackson, MD, MPH Jennifer Nelson, PhD Lora Bounds Marshfield Clinic Rsch. Foundation (MFC) Marshfield WI Edward Belongia, MD James Donahue, MD Nick Berger Health Partners Rsch Foundation (HPM) Minneapolis MN Jim Nordin, MD Amy Butani Kaiser Permanente of Colorado (KPC) Denver, CO Simon Hambidge, MD, PhD Jason Glanz, MS, PhD David McClure, PhD Matt Daley, MD David Ryerson So. California Kaiser Permanente (SCK), CA Los Angeles, CA Steven Jacobson, MD, PhD Wansu Chen, MS Sungching Glenn, MS VSD Investigators and Collaborators - Partial List Sites include > 125 staff working on VSD

  49. Case Only Methods: Descriptive Epidemiology Observed vs. Background Rates of GBS: Crude and Age-Specific Comparisons Estimated GBS Rates in Vaccinated vs. Unvaccinated Persons: Crude and Age-Specific Comparisons Case-Cohort analysis BRFSS Vaccine Coverage Data Available Potential Analytic Studies: Self Control Case Series (SCCS) NOV DEC JAN FEB MAR APR MAY OCT EIP Guillain-Barre Surveillance Timeline Vaccine Delivered